NSE: EPIGRAL | BSE: 543332

Mid-range Performer

Download real time

979.30 -17.10 (-1.72%)

43.39% Fall from 52W High

70,532 NSE+BSE Volume

NSE 12 Oct, 2026 3:31 PM (IST)

4,224.8

Market Cap

Above industry Median

Beta 1Year

Very High Volatility

Epigral Ltd. share price target and research reports

Name: Latest research reports of Epigral Ltd. authored by Emkay and published by - Trendlyne research reports.
Item: Epigral Ltd.
Rating: 5
Author: Emkay

Latest analyst research reports with target prices and PDF download for EPIGRAL, BSE:543332 Epigral Ltd.

Search Inside the pdf :

Epigral Ltd.

06 May 2025

979.30

-1.72%

In-line quarter; volume growth guidance maintained

Buy: Epigral Ltd.

Target

Emkay

Epigral posted in-line results, with revenue/EBITDA/PAT up 20%/12%/12% YoY. This was largely led by improvement in ECUs in the caustic soda business and higher realizations for ECH (because of ADD), volume growth in the derivatives and specialty segment (CPVC, ECH).

Epigral has lost -42.93% in the last 1 Year

Epigral Ltd.

17 Apr 2025

979.30

-1.72%

India’s Leading Integrated Chemical Manufacturer

Buy: Epigral Ltd.

Target

FundsIndia

Commissioned India’s first Epichlorohydrin (ECH) plant using 100% renewable
resources.

Epigral Ltd. is trading below all available SMAs

Epigral Ltd.

30 Aug 2024

979.30

-1.72%

FundsIndia

Epigral has lost -42.93% in the last 1 Year

Epigral Ltd.

01 Jul 2024

979.30

-1.72%

Valorization to valuation story

Buy: Epigral Ltd.

Emkay

Epigral is poised to consistently grow its earnings at 25%+ CAGR over the next
few years, led by i) higher utilization/expansion of existing capacities, ii)
consumption of chlorine into derivatives/value-added products with large
import substitution opportunity

Epigral Ltd. is trading below all available SMAs

VOTE: Is Meghmani Finechem Ltd. worth buying?

102 Votes:

Buy 86.27%

Sell 9.8%

Hold 3.92%